PMD
Psychemedics Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.67
+0.00%Year over year
Reported trailing growth
- Revenue
- -10.9%
- EBITDA
- -4.8%
- EBIT
- +35.2%
- EPS
- +55.6%
- Free cash flow
- +154.3%
- Operating cash flow
- +162.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.5%
- EBITDA
- -63.4%
- EBIT
- +35.2%
- Net income
- +55.2%
- EPS
- +55.6%
- Free cash flow
- +53.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2024